Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCeiba Investme. Regulatory News (CBA)

Share Price Information for Ceiba Investme. (CBA)

Share Price is delayed by 15 minutes
Get Live Data
29.00    0.00 (0.00%)
Bid:
24.00
Ask:
34.00
Spread: 10.00 (41.667%)
Market Cap: £47.91m
CBA Live PriceLast checked at - London Stock Exchange

Intraday Ceiba Investme. Share Chart

Issue of Equity

12 May 2026 07:00

RNS Number : 8531D
Ceiba Investments Limited
12 May 2026
 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA, IN ANY MEMBER STATE OF THE EEA OR IN ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL.

 

This announcement is not an offer to sell, or a solicitation of an offer to acquire, securities in any jurisdiction in which the same would be unlawful. Neither this announcement nor any part of it shall form the basis of or be relied on in connection with or act as an inducement to enter into any contract or commitment whatsoever. This announcement contains inside information.

 

 

CEIBA INVESTMENTS LIMITED

(the "Company")

(TICKER CBA, ISIN: GG00BFMDJH11)

Legal Entity Identifier: 213800XGY151JV5B1E88

 

 

 

ISSUE OF EQUITY

 

 

The Board of CEIBA Investments Limited is pleased to announce that it has successfully raised gross proceeds of £10,463,040 before expenses by way of a subscription (the "Subscription"), through the issue of 27,534,315 new Ordinary Shares in the Company ("Subscription Shares") at a price of 38 pence per share (the "Subscription Price"). The Subscription Price represents a premium of approximately 31.03 per cent to the closing share price on 8 May 2026 and a discount of approximately 39.78 per cent to the Company's prevailing net asset value per share of 63.1 pence per share as at 31 December 2025. All of the Subscription Shares were issued under the authority granted at the Company's extraordinary general meeting on 14 April 2026 ("EGM") to a new strategic investor in the Company. As a result of the Subscription the new strategic investor will hold a 16.67% interest in the share capital of the Company. The Subscription follows detailed discussions and the execution of a letter of intent after the EGM, which required, among other things, full exclusivity over the Subscription and the ability to nominate a director of the Company for so long as the strategic investor maintains a holding of 15% or more of the Company's total voting rights. 

In proceeding with the Subscription with a single new investor, the Company was mindful of the need to secure full and immediate funding on reasonable terms with a strategic investor in order to safeguard the Company's future for the benefit of all shareholders.

The net proceeds of the Subscription will be used to make a further payment of deferred fees to the Company's former Manager, Aberdeen Group Plc (US$625,987, plus accrued interest), and pay an amount of €5 million in principal, plus accrued interest in respect of Segment B of the €25 million senior unsecured convertible bonds, of which (following this payment) an amount of €15 million will remain outstanding.

The remaining proceeds will be applied to strengthen the liquidity position and working capital of the Company so that the Company can continue its ongoing operations despite the current difficulties linked to the energy and oil supply crisis in Cuba.

 

Admission and Total Voting Rights

Application has been made for the admission of the Subscription Shares to trading on the Specialist Fund Segment of the LSE's main market and dealings are expected to commence on or before 13 May 2026 ("Admission"). The Subscription Shares will be issued credited as fully paid and will, on issue, rank pari passu in all respects with the existing Ordinary Shares in issue, including the right to receive all dividends and other distributions thereafter declared, made or paid on the enlarged share capital from Admission.

Following Admission of the Subscription Shares, the Company's total issued share capital will consist of 165,205,891 Ordinary Shares in the Company. There are no shares held in treasury. The above figure (165,205,891 Ordinary Shares) may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, CEIBA Investments Limited under the FCA's Disclosure Guidance and Transparency Rules.

As a result of the 31 December 2025 year end results of the Company and the dilutive effect of the issue, the Conversion Price of the Convertible Bonds has changed from 66 pence to 62 pence.

 

For further information, please contact:

 

Sebastiaan Berger Via NSM Funds Limited 

 

Singer Capital Markets Tel: +44 (0)20 7496 3000

James Maxwell / Patrick Weaver (Corporate Finance) 

Sam Greatrex (Sales) 

 

NSM Funds Limited Tel: +44 (0)1481 743030

 

 

www.ceibainvest.com

 

This announcement contains inside information. The person responsible for arranging for the release of this announcement on behalf of the Company is NSM Funds Limited as Secretary of the Company.

 

 

END OF ANNOUNCEMENT

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEEFLFFQELEBBB
12
Date   Source Headline
5th Jun 20268:33 amRNSTrading Update
27th May 20263:39 pmRNSHolding(s) in Company
22nd May 20262:30 pmRNSHolding(s) in Company
20th May 20263:37 pmRNSHolding(s) in Company
19th May 20261:07 pmRNSHolding(s) in Company
15th May 202612:40 pmRNSDirector/PDMR Shareholding
12th May 20267:00 amRNSIssue of Equity
30th Apr 20267:00 amRNSAnnual Financial Report
14th Apr 20264:46 pmRNSResult of EGM
1st Apr 202611:21 amRNSFurther re Second Amendment of Bond Instrument
27th Feb 20265:14 pmRNSFurther re Second Amendment of Bond Instrument
27th Feb 20262:26 pmRNSDirectorate change
13th Feb 20265:13 pmRNSStatement re Second Amendment of Bond Instrument
13th Feb 20263:20 pmRNSDirector Declaration
12th Feb 20265:32 pmRNSChange of Auditor
5th Feb 20267:00 amRNSTrading Update - Consultation with Bondholders
26th Jan 20263:36 pmRNSDirector/PDMR Shareholding
23rd Dec 20251:39 pmRNSNet Asset Value(s)
4th Dec 20253:25 pmRNSAppointment of Senior Independent Director
2nd Oct 20252:48 pmRNSDirector/PDMR Shareholding
29th Sep 20257:00 amRNSHalf-year Report
12th Sep 20253:16 pmRNSDirectorate Change
8th Jul 20257:00 amRNSTrading Update - Payment to Bondholders
4th Jul 202512:49 pmRNSDirectorate Change
3rd Jul 20253:14 pmRNSResult of AGM
1st Jul 20251:35 pmRNSNet Asset Value(s)
30th Apr 20257:00 amRNSAnnual Financial Report
28th Apr 202510:26 amRNSDirectorate Change
3rd Feb 20257:00 amRNSStatement re Amendment of Bond Instrument
13th Jan 20255:51 pmRNSStatement re Amendment of Bond Instrument
11th Dec 20241:31 pmRNSNet Asset Value(s)
7th Oct 202410:55 amRNSDirector/PDMR Shareholding
7th Oct 20247:00 amRNSStatement re Update from the Chairman
27th Sep 20247:00 amRNSHalf-year Report to 30 June 2024
13th Aug 20248:36 amRNSDirectorate Change
20th Jun 20243:09 pmRNSDirector/PDMR Shareholding
20th Jun 20247:00 amRNSNet Asset Value(s)
18th Jun 20244:53 pmRNSResult of AGM
30th Apr 20247:00 amRNSAnnual Financial Report
25th Mar 202411:03 amRNSDirectorate Change
17th Jan 20247:00 amRNSInvestment Update
27th Dec 20239:17 amRNSNet Asset Value(s)
18th Dec 20238:54 amRNSDirector/PDMR Shareholding
3rd Nov 202310:36 amRNSHolding(s) in Company
1st Nov 20239:05 amRNSDirector/PDMR Shareholding
27th Oct 202311:11 amRNSDirector/PDMR Shareholding
16th Oct 20238:37 amRNSAppointment of Non-Executive Director
12th Oct 20234:26 pmRNSDirector/PDMR Shareholding
5th Oct 202310:24 amRNSDirector/PDMR Shareholding
29th Sep 20237:00 amRNSHalf-year Report
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.